 Shawn McCandless
Concepts (391)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neonatal Screening | 12 | 2020 | 177 | 2.220 |
Why?
| | Prader-Willi Syndrome | 8 | 2024 | 30 | 2.090 |
Why?
| | Urea Cycle Disorders, Inborn | 16 | 2020 | 26 | 1.930 |
Why?
| | Phenylbutyrates | 12 | 2020 | 23 | 1.190 |
Why?
| | Metabolism, Inborn Errors | 6 | 2021 | 42 | 1.060 |
Why?
| | Glycerol | 11 | 2020 | 89 | 1.060 |
Why?
| | Hyperphagia | 4 | 2024 | 39 | 0.810 |
Why?
| | Abnormalities, Multiple | 6 | 2013 | 196 | 0.790 |
Why?
| | Phenylketonurias | 3 | 2023 | 15 | 0.740 |
Why?
| | Ammonia | 9 | 2020 | 63 | 0.720 |
Why?
| | Glutamine | 9 | 2018 | 109 | 0.640 |
Why?
| | Infant, Newborn | 28 | 2022 | 6406 | 0.620 |
Why?
| | Chromosome Deletion | 4 | 2010 | 127 | 0.590 |
Why?
| | Galactosemias | 1 | 2019 | 16 | 0.580 |
Why?
| | Cinnamates | 1 | 2017 | 12 | 0.530 |
Why?
| | Aminopeptidases | 1 | 2017 | 21 | 0.530 |
Why?
| | Cyclohexanes | 1 | 2017 | 23 | 0.530 |
Why?
| | Appetite Depressants | 1 | 2017 | 19 | 0.530 |
Why?
| | Epoxy Compounds | 1 | 2017 | 32 | 0.520 |
Why?
| | Sesquiterpenes | 1 | 2017 | 52 | 0.510 |
Why?
| | Protease Inhibitors | 1 | 2017 | 103 | 0.500 |
Why?
| | Acidosis | 1 | 2017 | 105 | 0.500 |
Why?
| | Genetic Testing | 4 | 2023 | 479 | 0.480 |
Why?
| | Lysosomal Storage Diseases | 1 | 2015 | 5 | 0.470 |
Why?
| | Glycoproteins | 1 | 2017 | 357 | 0.450 |
Why?
| | Public Health | 1 | 2020 | 561 | 0.440 |
Why?
| | Hyperammonemia | 4 | 2020 | 18 | 0.430 |
Why?
| | Parenteral Nutrition | 1 | 2015 | 105 | 0.420 |
Why?
| | Infant | 25 | 2024 | 9987 | 0.400 |
Why?
| | Consanguinity | 1 | 2013 | 49 | 0.400 |
Why?
| | Hazardous Substances | 1 | 2012 | 15 | 0.380 |
Why?
| | Lipid Metabolism, Inborn Errors | 1 | 2012 | 20 | 0.380 |
Why?
| | Child, Preschool | 27 | 2024 | 11740 | 0.370 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2013 | 766 | 0.360 |
Why?
| | Obesity | 2 | 2017 | 3107 | 0.340 |
Why?
| | Amino Acids | 1 | 2015 | 520 | 0.340 |
Why?
| | Phenylalanine | 4 | 2023 | 71 | 0.310 |
Why?
| | Humans | 72 | 2024 | 144857 | 0.310 |
Why?
| | Rare Diseases | 5 | 2019 | 113 | 0.300 |
Why?
| | Child | 30 | 2024 | 22620 | 0.290 |
Why?
| | Phenylacetates | 4 | 2020 | 10 | 0.280 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 1178 | 0.260 |
Why?
| | Acyl-CoA Dehydrogenases | 2 | 2024 | 12 | 0.250 |
Why?
| | Adolescent | 22 | 2024 | 22396 | 0.250 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2013 | 2186 | 0.250 |
Why?
| | Feeding Behavior | 1 | 2012 | 684 | 0.250 |
Why?
| | Acidosis, Lactic | 2 | 2024 | 46 | 0.240 |
Why?
| | Male | 40 | 2024 | 72189 | 0.230 |
Why?
| | Female | 42 | 2024 | 78217 | 0.230 |
Why?
| | Young Adult | 15 | 2024 | 14033 | 0.220 |
Why?
| | Chromosomes, Human, Pair 3 | 1 | 2005 | 44 | 0.220 |
Why?
| | Infant Formula | 2 | 2018 | 71 | 0.220 |
Why?
| | Chromosomes, Human, Pair 21 | 1 | 2005 | 42 | 0.220 |
Why?
| | Methionine | 2 | 2021 | 163 | 0.210 |
Why?
| | Bezafibrate | 1 | 2024 | 10 | 0.210 |
Why?
| | Mutation | 8 | 2019 | 4132 | 0.210 |
Why?
| | Pyridinium Compounds | 1 | 2024 | 31 | 0.210 |
Why?
| | Diazoxide | 1 | 2024 | 21 | 0.210 |
Why?
| | Trisomy | 1 | 2005 | 78 | 0.210 |
Why?
| | False Positive Reactions | 2 | 2015 | 126 | 0.200 |
Why?
| | Neutropenia | 2 | 2022 | 156 | 0.200 |
Why?
| | Vitamin B 12 | 2 | 2021 | 127 | 0.200 |
Why?
| | Niacinamide | 1 | 2024 | 86 | 0.200 |
Why?
| | Growth Disorders | 2 | 2019 | 86 | 0.200 |
Why?
| | Genetic Diseases, Inborn | 1 | 2003 | 44 | 0.200 |
Why?
| | Delayed-Action Preparations | 1 | 2024 | 183 | 0.200 |
Why?
| | Face | 2 | 2020 | 173 | 0.190 |
Why?
| | Mass Spectrometry | 3 | 2004 | 748 | 0.190 |
Why?
| | Glycogen Storage Disease Type I | 1 | 2022 | 9 | 0.190 |
Why?
| | Phenotype | 7 | 2019 | 3199 | 0.180 |
Why?
| | Leukodystrophy, Metachromatic | 1 | 2001 | 4 | 0.180 |
Why?
| | Cost of Illness | 1 | 2003 | 321 | 0.170 |
Why?
| | Metabolism | 1 | 2021 | 44 | 0.170 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2000 | 19 | 0.170 |
Why?
| | Strabismus | 1 | 2021 | 70 | 0.170 |
Why?
| | Amino Acid Metabolism, Inborn Errors | 2 | 2021 | 24 | 0.170 |
Why?
| | Acyl-CoA Dehydrogenase | 3 | 2012 | 8 | 0.160 |
Why?
| | Prenatal Care | 1 | 2023 | 306 | 0.160 |
Why?
| | Cardiomyopathies | 1 | 2024 | 335 | 0.160 |
Why?
| | Hospitals, Pediatric | 1 | 2003 | 554 | 0.160 |
Why?
| | Double-Blind Method | 4 | 2023 | 2030 | 0.150 |
Why?
| | Orphan Drug Production | 1 | 2019 | 5 | 0.150 |
Why?
| | Alleles | 3 | 2019 | 883 | 0.150 |
Why?
| | Mental Status and Dementia Tests | 1 | 2019 | 26 | 0.150 |
Why?
| | Vitamin B 12 Deficiency | 1 | 2019 | 78 | 0.150 |
Why?
| | Adult | 18 | 2024 | 40438 | 0.150 |
Why?
| | DNA Polymerase II | 1 | 2018 | 35 | 0.140 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2018 | 36 | 0.140 |
Why?
| | Osteochondrodysplasias | 1 | 2018 | 20 | 0.140 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2023 | 425 | 0.140 |
Why?
| | Skin Abnormalities | 1 | 1998 | 12 | 0.140 |
Why?
| | Polycomb Repressive Complex 2 | 1 | 2019 | 82 | 0.140 |
Why?
| | Adrenal Insufficiency | 1 | 2018 | 29 | 0.140 |
Why?
| | Eye Abnormalities | 1 | 1998 | 17 | 0.140 |
Why?
| | Goldenhar Syndrome | 1 | 1998 | 11 | 0.140 |
Why?
| | Sensitivity and Specificity | 3 | 2017 | 1987 | 0.140 |
Why?
| | Registries | 4 | 2021 | 2253 | 0.140 |
Why?
| | Diagnosis, Differential | 3 | 2017 | 1504 | 0.140 |
Why?
| | Fructose Intolerance | 1 | 2018 | 5 | 0.140 |
Why?
| | Fructose-Bisphosphate Aldolase | 1 | 2018 | 10 | 0.140 |
Why?
| | Chromosomes, Human, Pair 22 | 1 | 1998 | 46 | 0.140 |
Why?
| | Fetus | 1 | 2023 | 803 | 0.140 |
Why?
| | Endpoint Determination | 1 | 2018 | 83 | 0.140 |
Why?
| | Exome | 1 | 2019 | 239 | 0.140 |
Why?
| | Lipase | 1 | 2018 | 72 | 0.140 |
Why?
| | Prodrugs | 1 | 2018 | 52 | 0.140 |
Why?
| | Urogenital Abnormalities | 1 | 2018 | 71 | 0.140 |
Why?
| | Pyruvate Dehydrogenase Complex | 1 | 2017 | 9 | 0.130 |
Why?
| | Pyruvate Dehydrogenase Complex Deficiency Disease | 1 | 2017 | 6 | 0.130 |
Why?
| | Methionyl Aminopeptidases | 1 | 2017 | 1 | 0.130 |
Why?
| | Enzyme Assays | 1 | 2017 | 25 | 0.130 |
Why?
| | Early Termination of Clinical Trials | 1 | 2017 | 18 | 0.130 |
Why?
| | Pediatricians | 1 | 2019 | 122 | 0.130 |
Why?
| | Intention to Treat Analysis | 1 | 2017 | 80 | 0.130 |
Why?
| | Ketones | 1 | 2017 | 52 | 0.130 |
Why?
| | Syndrome | 4 | 2020 | 377 | 0.130 |
Why?
| | Glutaryl-CoA Dehydrogenase | 1 | 2016 | 5 | 0.120 |
Why?
| | Brain Diseases, Metabolic | 1 | 2016 | 8 | 0.120 |
Why?
| | Parents | 3 | 2020 | 1424 | 0.120 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2018 | 138 | 0.120 |
Why?
| | Body Mass Index | 2 | 2017 | 2448 | 0.120 |
Why?
| | Imaging, Three-Dimensional | 1 | 2020 | 586 | 0.120 |
Why?
| | Patient Preference | 1 | 2018 | 220 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 2103 | 0.110 |
Why?
| | Indians, North American | 1 | 2001 | 658 | 0.110 |
Why?
| | Prevalence | 2 | 2012 | 2830 | 0.110 |
Why?
| | Venous Thrombosis | 1 | 2017 | 194 | 0.110 |
Why?
| | United States | 6 | 2020 | 15723 | 0.110 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2015 | 75 | 0.110 |
Why?
| | Cognition | 2 | 2023 | 1262 | 0.110 |
Why?
| | Mosaicism | 2 | 2005 | 75 | 0.110 |
Why?
| | Mitochondrial Encephalomyopathies | 1 | 2013 | 9 | 0.100 |
Why?
| | Genetic Counseling | 1 | 2014 | 83 | 0.100 |
Why?
| | Biomarkers | 4 | 2024 | 4279 | 0.100 |
Why?
| | Hepatic Encephalopathy | 1 | 2013 | 20 | 0.100 |
Why?
| | Genotype | 1 | 2019 | 1841 | 0.100 |
Why?
| | Fibroblasts | 2 | 2017 | 1042 | 0.100 |
Why?
| | Rape | 1 | 2013 | 35 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2017 | 2037 | 0.100 |
Why?
| | Cohort Studies | 3 | 2024 | 5898 | 0.090 |
Why?
| | Fetal Growth Retardation | 1 | 2018 | 591 | 0.090 |
Why?
| | Ubiquinone | 1 | 2012 | 35 | 0.090 |
Why?
| | Siblings | 1 | 2013 | 196 | 0.090 |
Why?
| | Drug Substitution | 1 | 2013 | 62 | 0.090 |
Why?
| | Mitochondrial Diseases | 1 | 2012 | 92 | 0.090 |
Why?
| | Intellectual Disability | 3 | 2019 | 176 | 0.090 |
Why?
| | Carnitine | 2 | 2003 | 89 | 0.090 |
Why?
| | Weight Loss | 1 | 2017 | 842 | 0.090 |
Why?
| | Severity of Illness Index | 2 | 2017 | 2940 | 0.080 |
Why?
| | Chromosomes, Human, Pair 19 | 1 | 2010 | 27 | 0.080 |
Why?
| | Urinary Tract | 1 | 1991 | 48 | 0.080 |
Why?
| | Ectodermal Dysplasia | 1 | 2010 | 19 | 0.080 |
Why?
| | 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase | 2 | 2021 | 17 | 0.080 |
Why?
| | Self Report | 1 | 2015 | 871 | 0.080 |
Why?
| | Homocysteine | 2 | 2021 | 151 | 0.080 |
Why?
| | Diseases in Twins | 1 | 1991 | 116 | 0.080 |
Why?
| | Diaphragm | 1 | 2010 | 49 | 0.080 |
Why?
| | Infant, Premature | 1 | 2015 | 612 | 0.080 |
Why?
| | Vaginal Diseases | 1 | 2010 | 18 | 0.080 |
Why?
| | Risk | 1 | 2012 | 905 | 0.080 |
Why?
| | Surveys and Questionnaires | 4 | 2022 | 6052 | 0.080 |
Why?
| | Chromosome Banding | 2 | 2010 | 17 | 0.080 |
Why?
| | Caregivers | 1 | 2018 | 1041 | 0.080 |
Why?
| | Heart Defects, Congenital | 3 | 2010 | 898 | 0.080 |
Why?
| | Algorithms | 1 | 2017 | 1848 | 0.070 |
Why?
| | alpha-Glucosidases | 1 | 2009 | 9 | 0.070 |
Why?
| | Glycogen Storage Disease Type II | 1 | 2009 | 6 | 0.070 |
Why?
| | Liver | 3 | 2013 | 1853 | 0.070 |
Why?
| | Cysts | 1 | 2010 | 111 | 0.070 |
Why?
| | Abdomen | 1 | 2010 | 142 | 0.070 |
Why?
| | Mental Disorders | 1 | 1998 | 1137 | 0.070 |
Why?
| | Cytomegalovirus Infections | 1 | 2010 | 207 | 0.070 |
Why?
| | Middle Aged | 10 | 2021 | 35939 | 0.070 |
Why?
| | Gene Frequency | 2 | 2016 | 485 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5350 | 0.070 |
Why?
| | Ultrasonography, Prenatal | 1 | 2010 | 295 | 0.070 |
Why?
| | Overweight | 1 | 2012 | 611 | 0.060 |
Why?
| | Iduronate Sulfatase | 1 | 2006 | 2 | 0.060 |
Why?
| | Mucopolysaccharidosis II | 1 | 2006 | 2 | 0.060 |
Why?
| | Cooperative Behavior | 1 | 2010 | 463 | 0.060 |
Why?
| | Respiratory Insufficiency | 1 | 2010 | 333 | 0.060 |
Why?
| | Cross-Over Studies | 3 | 2014 | 600 | 0.060 |
Why?
| | In Situ Hybridization, Fluorescence | 2 | 2005 | 322 | 0.060 |
Why?
| | Sex Factors | 1 | 2012 | 2090 | 0.060 |
Why?
| | Time Factors | 2 | 2015 | 7107 | 0.060 |
Why?
| | Brain | 1 | 1998 | 2934 | 0.060 |
Why?
| | Muscle, Skeletal | 2 | 2013 | 1810 | 0.060 |
Why?
| | Echocardiography | 2 | 2024 | 642 | 0.060 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2006 | 179 | 0.060 |
Why?
| | Karyotyping | 1 | 2005 | 107 | 0.050 |
Why?
| | Chromosome Disorders | 1 | 2005 | 45 | 0.050 |
Why?
| | Diet | 1 | 2012 | 1277 | 0.050 |
Why?
| | Retrospective Studies | 3 | 2022 | 16937 | 0.050 |
Why?
| | Fragile X Syndrome | 1 | 2005 | 118 | 0.050 |
Why?
| | Disease Management | 2 | 2019 | 639 | 0.050 |
Why?
| | Fatal Outcome | 2 | 2010 | 306 | 0.050 |
Why?
| | Radiography | 2 | 2010 | 839 | 0.050 |
Why?
| | Microcephaly | 1 | 2005 | 103 | 0.050 |
Why?
| | Gene Deletion | 1 | 2005 | 388 | 0.050 |
Why?
| | X Chromosome | 2 | 2000 | 69 | 0.050 |
Why?
| | Heterozygote | 2 | 2001 | 316 | 0.050 |
Why?
| | Neuropsychological Tests | 3 | 2019 | 1124 | 0.050 |
Why?
| | Lymphocytes | 3 | 2017 | 396 | 0.050 |
Why?
| | Anxiety | 2 | 2023 | 1114 | 0.050 |
Why?
| | Pregnancy | 4 | 2023 | 7197 | 0.050 |
Why?
| | Hyperhomocysteinemia | 1 | 2003 | 27 | 0.050 |
Why?
| | Carbon-Carbon Ligases | 1 | 2003 | 2 | 0.050 |
Why?
| | Food, Fortified | 1 | 2003 | 43 | 0.050 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 258 | 0.050 |
Why?
| | Drug Combinations | 1 | 2024 | 381 | 0.050 |
Why?
| | Pedigree | 2 | 2001 | 514 | 0.050 |
Why?
| | Quality of Life | 1 | 2015 | 3165 | 0.050 |
Why?
| | Oxytocin | 1 | 2023 | 51 | 0.050 |
Why?
| | Cough | 2 | 2017 | 135 | 0.050 |
Why?
| | Infant Food | 1 | 2003 | 64 | 0.050 |
Why?
| | Models, Genetic | 1 | 2005 | 536 | 0.050 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2022 | 89 | 0.040 |
Why?
| | Glucosides | 1 | 2022 | 56 | 0.040 |
Why?
| | Founder Effect | 1 | 2001 | 13 | 0.040 |
Why?
| | Benzhydryl Compounds | 1 | 2022 | 83 | 0.040 |
Why?
| | Developmental Disabilities | 1 | 2005 | 295 | 0.040 |
Why?
| | Homozygote | 2 | 2018 | 201 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2005 | 600 | 0.040 |
Why?
| | History, 19th Century | 1 | 2001 | 61 | 0.040 |
Why?
| | Workflow | 1 | 2023 | 187 | 0.040 |
Why?
| | United States Indian Health Service | 1 | 2001 | 46 | 0.040 |
Why?
| | RNA-Binding Proteins | 1 | 2005 | 468 | 0.040 |
Why?
| | Hand Deformities, Congenital | 1 | 2000 | 10 | 0.040 |
Why?
| | Diet, Ketogenic | 1 | 2021 | 38 | 0.040 |
Why?
| | Ribosomal Protein S6 Kinases | 1 | 2000 | 24 | 0.040 |
Why?
| | Facies | 1 | 2000 | 22 | 0.040 |
Why?
| | Warfare | 1 | 2001 | 96 | 0.040 |
Why?
| | Betaine | 1 | 2000 | 65 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2021 | 170 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2021 | 247 | 0.040 |
Why?
| | Methyltransferases | 1 | 2000 | 74 | 0.040 |
Why?
| | History, 20th Century | 1 | 2001 | 328 | 0.040 |
Why?
| | Vitamins | 1 | 2021 | 177 | 0.040 |
Why?
| | Nucleocytoplasmic Transport Proteins | 1 | 2019 | 9 | 0.040 |
Why?
| | Drug Industry | 1 | 2019 | 49 | 0.040 |
Why?
| | Public-Private Sector Partnerships | 1 | 2019 | 45 | 0.040 |
Why?
| | Angelman Syndrome | 1 | 1999 | 10 | 0.040 |
Why?
| | Mutation, Missense | 1 | 2001 | 342 | 0.040 |
Why?
| | Adrenoleukodystrophy | 1 | 1999 | 8 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p57 | 1 | 2018 | 5 | 0.040 |
Why?
| | Genomic Imprinting | 1 | 1999 | 26 | 0.040 |
Why?
| | Ornithine Carbamoyltransferase Deficiency Disease | 1 | 2019 | 7 | 0.040 |
Why?
| | Cell Line | 1 | 2005 | 2911 | 0.040 |
Why?
| | Age of Onset | 1 | 2020 | 544 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2019 | 139 | 0.040 |
Why?
| | Incidence | 2 | 2021 | 2865 | 0.040 |
Why?
| | Attention Deficit and Disruptive Behavior Disorders | 1 | 1999 | 55 | 0.040 |
Why?
| | MAP Kinase Signaling System | 1 | 2000 | 316 | 0.040 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 5809 | 0.040 |
Why?
| | Urea | 1 | 2019 | 84 | 0.040 |
Why?
| | Nutritional Status | 1 | 2021 | 353 | 0.040 |
Why?
| | Executive Function | 1 | 2023 | 459 | 0.030 |
Why?
| | Delayed Diagnosis | 1 | 2019 | 95 | 0.030 |
Why?
| | Canada | 1 | 2019 | 425 | 0.030 |
Why?
| | North America | 1 | 2019 | 309 | 0.030 |
Why?
| | Pyruvate Dehydrogenase (Lipoamide) | 1 | 2017 | 10 | 0.030 |
Why?
| | Europe | 1 | 2019 | 412 | 0.030 |
Why?
| | Length of Stay | 1 | 2003 | 1321 | 0.030 |
Why?
| | Cleft Lip | 1 | 1998 | 72 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 1997 | 306 | 0.030 |
Why?
| | Biochemistry | 1 | 2017 | 36 | 0.030 |
Why?
| | Nitrogen | 1 | 2018 | 169 | 0.030 |
Why?
| | Cleft Palate | 1 | 1998 | 89 | 0.030 |
Why?
| | Skull | 1 | 1998 | 155 | 0.030 |
Why?
| | Proteomics | 1 | 2024 | 1196 | 0.030 |
Why?
| | Child Behavior Disorders | 1 | 1998 | 125 | 0.030 |
Why?
| | Recombinant Proteins | 3 | 2006 | 1358 | 0.030 |
Why?
| | DNA Replication | 1 | 2018 | 259 | 0.030 |
Why?
| | Glutarates | 1 | 2016 | 11 | 0.030 |
Why?
| | Renal Dialysis | 1 | 2020 | 460 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2019 | 450 | 0.030 |
Why?
| | Cocaine | 1 | 1998 | 162 | 0.030 |
Why?
| | Global Health | 1 | 2019 | 395 | 0.030 |
Why?
| | Lipids | 1 | 2021 | 701 | 0.030 |
Why?
| | Fever | 1 | 2017 | 311 | 0.030 |
Why?
| | Child Behavior | 1 | 1998 | 239 | 0.030 |
Why?
| | Prospective Studies | 2 | 2019 | 7947 | 0.030 |
Why?
| | Glucose | 1 | 2021 | 1048 | 0.030 |
Why?
| | Cognition Disorders | 1 | 1999 | 542 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1685 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 685 | 0.030 |
Why?
| | North Carolina | 2 | 2006 | 130 | 0.030 |
Why?
| | Fasting | 1 | 2015 | 282 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2005 | 2914 | 0.030 |
Why?
| | Primary Health Care | 1 | 2004 | 1763 | 0.030 |
Why?
| | Immunoglobulin G | 2 | 2009 | 899 | 0.020 |
Why?
| | Enzyme Stability | 2 | 2004 | 73 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2016 | 576 | 0.020 |
Why?
| | Biomarkers, Pharmacological | 1 | 2012 | 26 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2023 | 11581 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 1998 | 594 | 0.020 |
Why?
| | Pediatrics | 1 | 2020 | 1099 | 0.020 |
Why?
| | DNA Mutational Analysis | 2 | 2005 | 408 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2004 | 379 | 0.020 |
Why?
| | Liver Transplantation | 1 | 2019 | 792 | 0.020 |
Why?
| | Blood Grouping and Crossmatching | 1 | 1991 | 17 | 0.020 |
Why?
| | DNA | 2 | 2010 | 1430 | 0.020 |
Why?
| | Transcription Factors | 1 | 2019 | 1741 | 0.020 |
Why?
| | Alcohol Drinking | 1 | 1998 | 832 | 0.020 |
Why?
| | Physical Chromosome Mapping | 1 | 2010 | 20 | 0.020 |
Why?
| | Chromosomes, Artificial, Bacterial | 1 | 2010 | 20 | 0.020 |
Why?
| | Chromosome Breakage | 1 | 2010 | 22 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2010 | 30 | 0.020 |
Why?
| | Age Factors | 1 | 2018 | 3311 | 0.020 |
Why?
| | Muscle Hypotonia | 1 | 2010 | 33 | 0.020 |
Why?
| | Twins, Monozygotic | 1 | 1991 | 134 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2012 | 779 | 0.020 |
Why?
| | Colpotomy | 1 | 2010 | 2 | 0.020 |
Why?
| | HLA Antigens | 1 | 1991 | 227 | 0.020 |
Why?
| | Interinstitutional Relations | 1 | 2010 | 52 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4177 | 0.020 |
Why?
| | Glycogen | 1 | 2009 | 55 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4253 | 0.020 |
Why?
| | Tracheostomy | 1 | 2010 | 142 | 0.020 |
Why?
| | Pilot Projects | 2 | 2006 | 1873 | 0.020 |
Why?
| | Escherichia coli | 2 | 2004 | 854 | 0.020 |
Why?
| | Body Height | 1 | 2009 | 202 | 0.020 |
Why?
| | Vagina | 1 | 2010 | 202 | 0.020 |
Why?
| | Skin Diseases | 1 | 2009 | 151 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2013 | 1701 | 0.020 |
Why?
| | Aged | 2 | 2018 | 25822 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 858 | 0.020 |
Why?
| | Glycosaminoglycans | 1 | 2006 | 79 | 0.020 |
Why?
| | Kaplan-Meier Estimate | 1 | 2009 | 960 | 0.020 |
Why?
| | Research Design | 1 | 2012 | 1128 | 0.010 |
Why?
| | False Negative Reactions | 1 | 2006 | 63 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2018 | 8185 | 0.010 |
Why?
| | Biomedical Research | 1 | 2012 | 716 | 0.010 |
Why?
| | Blood Specimen Collection | 1 | 2006 | 39 | 0.010 |
Why?
| | Joints | 1 | 2006 | 109 | 0.010 |
Why?
| | Infusions, Intravenous | 1 | 2006 | 427 | 0.010 |
Why?
| | Blotting, Southern | 1 | 2005 | 85 | 0.010 |
Why?
| | Respiration, Artificial | 1 | 2010 | 714 | 0.010 |
Why?
| | Myristic Acid | 1 | 2004 | 10 | 0.010 |
Why?
| | Respiratory Function Tests | 1 | 2006 | 572 | 0.010 |
Why?
| | Safety | 1 | 2006 | 353 | 0.010 |
Why?
| | Spleen | 1 | 2006 | 518 | 0.010 |
Why?
| | Histidine | 1 | 2004 | 66 | 0.010 |
Why?
| | Body Weight | 1 | 2009 | 993 | 0.010 |
Why?
| | Circular Dichroism | 1 | 2004 | 150 | 0.010 |
Why?
| | Mitochondria, Liver | 1 | 2004 | 69 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2015 | 2224 | 0.010 |
Why?
| | Tyrosine | 1 | 2004 | 227 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2004 | 304 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2004 | 569 | 0.010 |
Why?
| | Acids | 1 | 2003 | 18 | 0.010 |
Why?
| | Brain Edema | 1 | 2003 | 62 | 0.010 |
Why?
| | Fatty Acids | 1 | 2006 | 451 | 0.010 |
Why?
| | Glutamic Acid | 1 | 2004 | 252 | 0.010 |
Why?
| | Lysine | 1 | 2004 | 302 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2010 | 2971 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2188 | 0.010 |
Why?
| | Chaperonin 10 | 1 | 2001 | 2 | 0.010 |
Why?
| | Chaperonin 60 | 1 | 2001 | 13 | 0.010 |
Why?
| | Infant Nutritional Physiological Phenomena | 1 | 2003 | 149 | 0.010 |
Why?
| | Prion Proteins | 1 | 2000 | 4 | 0.010 |
Why?
| | Chromosomes, Human, Pair 5 | 1 | 2000 | 30 | 0.010 |
Why?
| | Betaine-Homocysteine S-Methyltransferase | 1 | 2000 | 9 | 0.010 |
Why?
| | Two-Hybrid System Techniques | 1 | 2000 | 59 | 0.010 |
Why?
| | Oxidation-Reduction | 1 | 2004 | 1099 | 0.010 |
Why?
| | Prions | 1 | 2000 | 51 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2000 | 392 | 0.010 |
Why?
| | Protein Precursors | 1 | 2000 | 136 | 0.010 |
Why?
| | Amyloid | 1 | 2000 | 95 | 0.010 |
Why?
| | Exons | 1 | 2001 | 358 | 0.010 |
Why?
| | Protein Folding | 1 | 2001 | 283 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2000 | 513 | 0.010 |
Why?
| | Haplotypes | 1 | 2001 | 491 | 0.010 |
Why?
| | Models, Molecular | 1 | 2004 | 1603 | 0.010 |
Why?
| | Wechsler Scales | 1 | 1999 | 59 | 0.010 |
Why?
| | Sequence Deletion | 1 | 1999 | 194 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1999 | 274 | 0.010 |
Why?
| | Temperature | 1 | 2001 | 684 | 0.010 |
Why?
| | Neoplasms | 1 | 2013 | 2929 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2000 | 829 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2000 | 2149 | 0.010 |
Why?
| | Social Behavior | 1 | 1999 | 294 | 0.010 |
Why?
| | Polymerase Chain Reaction | 1 | 1999 | 1058 | 0.010 |
Why?
| | Rats | 1 | 2004 | 5632 | 0.010 |
Why?
| | Animals | 3 | 2004 | 38331 | 0.010 |
Why?
| | DNA Methylation | 1 | 1999 | 681 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2001 | 3411 | 0.010 |
Why?
| | Genetic Variation | 1 | 1997 | 991 | 0.010 |
Why?
| | Mice | 2 | 2000 | 18549 | 0.010 |
Why?
| | Disease Progression | 1 | 1999 | 2881 | 0.010 |
Why?
| | Magnetic Resonance Imaging | 1 | 2003 | 3861 | 0.010 |
Why?
|
|
McCandless's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|